PFM Health Sciences’s Syndax Pharmaceuticals SNDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-118,422
Closed -$2.59M – 118
2026
Q2
$2.59M Sell
118,422
-126,599
-52% -$2.63M 0.22% 83
2026
Q1
$5.72M Buy
245,021
+2,054
+0.8% +$44.6K 0.52% 60
2025
Q4
$5.1M Sell
242,967
-13,521
-5% -$236K 0.51% 52
2025
Q3
$3.95M Buy
+256,488
New +$3.36M 0.3% 56
2025
Q2
– Sell
-926,424
Closed -$11.4M – 70
2025
Q1
$11.4M Buy
926,424
+719,553
+348% +$10.1M 0.83% 29
2024
Q4
$2.73M Sell
206,871
-217,039
-51% -$3.71M 0.17% 67
2024
Q3
$8.16M Buy
423,910
+36,553
+9% +$755K 0.46% 44
2024
Q2
$7.95M Sell
387,357
-271,337
-41% -$5.68M 0.39% 50
2024
Q1
$15.7M Buy
658,694
+63,171
+11% +$1.41M 0.74% 44
2023
Q4
$12.9M Sell
595,523
-2,119,712
-78% -$32.6M 0.77% 43
2023
Q3
$39.4M Buy
2,715,235
+542,798
+25% +$10.3M 1.86% 25
2023
Q2
$45.5M Buy
2,172,437
+225,785
+12% +$4.7M 1.77% 22
2023
Q1
$41.1M Buy
1,946,652
+132,018
+7% +$3.28M 1.82% 20
2022
Q4
$46.2M Buy
1,814,634
+525,561
+41% +$12.3M 1.65% 24
2022
Q3
$31M Buy
1,289,073
+708,305
+122% +$15.9M 1.12% 44
2022
Q2
$11.2M Sell
580,768
-1,462,609
-72% -$24.4M 0.43% 57
2022
Q1
$35.5M Sell
2,043,377
-60,135
-3% -$1.01M 1.33% 36
2021
Q4
$46M Buy
2,103,512
+246,774
+13% +$4.56M 1.57% 28
2021
Q3
$35.5M Sell
1,856,738
-288,143
-13% -$4.8M 1.04% 41
2021
Q2
$36.8M Buy
2,144,881
+660,654
+45% +$12.1M 1.15% 33
2021
Q1
$33.2M Buy
+1,484,227
New +$33.5M 1.01% 39

Other funds holding SNDX

PFM Health Sciences's SNDX Position: Q3 2026 in Review

PFM Health Sciences sold out of Syndax Pharmaceuticals (SNDX) in Q3 2026, closing a stake of 118,422 shares — an estimated $2.59M sold.

PFM Health Sciences first reported a position in SNDX in Q1 2021 and held it in 21 quarters. The position peaked at $46.2M in Q4 2022. 237 funds tracked by Wall St. Rank hold SNDX as of Q3 2026.

  • PFM Health Sciences reported no remaining Syndax Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • PFM Health Sciences sold 118,422 Syndax Pharmaceuticals shares in Q3 2026, an estimated $2.59M.
  • PFM Health Sciences first reported a position in Syndax Pharmaceuticals in Q1 2021 and held it in 21 quarters.
  • PFM Health Sciences's Syndax Pharmaceuticals position peaked at $46.2M in Q4 2022.
  • 237 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2026.

Based on PFM Health Sciences's 13F filing for Q3 2026, filed 16 Nov 2026.